Market Research Logo

Swedish Orphan Biovitrum AB (SOBI) - Financial and Strategic SWOT Analysis Review

Swedish Orphan Biovitrum AB (SOBI) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Swedish Orphan Biovitrum AB (Sobi), formerly Biovitrum AB, is an integrated biopharmaceutical company that focuses on the development of products for the treatment of rare diseases. The company specializes in biotechnology with prime capabilities in protein biochemistry and biologics manufacturing. Its product portfolio principally focuses on haemophilia, inflammation and genetic and metabolic diseases. The products offered are Alprolix, Ammonaps, Elocta, Kepivance, Kineret and Orfadin. The company also manufactures and markets specialty and rare disease products for partner companies. It has operational presence in Europe, the Middle East and North Africa. Sobi is headquartered in Stockholm, Sweden.

Swedish Orphan Biovitrum AB Key Recent Developments

Jun 07,2017: Chief Operating Officer Alan Raffensperger to leave Sobi
Jun 05,2017: Sobi Keeps the Partner Products Business Area as an Integral Part of the Company
May 04,2017: Guido Oelkers Appointed President and CEO at Sobi
May 03,2017: Sobi opens office in Greece
Apr 07,2017: Theresa Heggie resigns from the Board of Directors and will not be proposed for re-election at Sobi’s annual general meeting 2017

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company 5
Swedish Orphan Biovitrum AB - Key Facts 5
Swedish Orphan Biovitrum AB - Key Employees 6
Swedish Orphan Biovitrum AB - Key Employee Biographies 7
Swedish Orphan Biovitrum AB - Major Products and Services 8
Swedish Orphan Biovitrum AB - History 9
Swedish Orphan Biovitrum AB - Company Statement 14
Swedish Orphan Biovitrum AB - Locations And Subsidiaries 15
Head Office 15
Other Locations & Subsidiaries 15
Section 2 – Company Analysis 17
Swedish Orphan Biovitrum AB - Business Description 17
Swedish Orphan Biovitrum AB - SWOT Analysis 18
SWOT Analysis - Overview 18
Swedish Orphan Biovitrum AB - Strengths 18
Swedish Orphan Biovitrum AB - Weaknesses 19
Swedish Orphan Biovitrum AB - Opportunities 20
Swedish Orphan Biovitrum AB - Threats 21
Swedish Orphan Biovitrum AB - Key Competitors 22
Section 3 – Company Financial Ratios 23
Financial Ratios - Capital Market Ratios 23
Financial Ratios - Annual Ratios 24
Performance Chart 27
Financial Performance 27
Financial Ratios - Interim Ratios 28
Financial Ratios - Ratio Charts 29
Section 4 – Company’s Lifesciences Financial Deals and Alliances 30
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 30
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 31
Swedish Orphan Biovitrum AB, Recent Deals Summary 32
Section 5 – Company’s Recent Developments 33
Jun 07, 2017: Chief Operating Officer Alan Raffensperger to leave Sobi 33
Jun 05, 2017: Sobi Keeps the Partner Products Business Area as an Integral Part of the Company 34
May 04, 2017: Guido Oelkers Appointed President and CEO at Sobi 35
Apr 07, 2017: Theresa Heggie resigns from the Board of Directors and will not be proposed for re-election at Sobi’s annual general meeting 2017 36
Feb 16, 2017: Sobi publishes its report for the fourth quarter and full year 2016 37
Jan 09, 2017: CEO Geoffrey McDonough to leave Swedish Orphan Biovitrum 38
Jan 05, 2017: Armin Reininger joins Sobi as Senior Vice President, Head of Global Medical and Scientific Affairs 39
Nov 14, 2016: European study of real-life haemophilia treatment emphasizes need to improve standard of care 40
Oct 27, 2016: Sobi publishes its report for the third quarter 2016, raises guidance 41
Oct 27, 2016: Swedish Orphan Biovitrum: Sobi Publishes Its Report for the Third Quarter 2016, Raises Guidance 42
Section 6 – Appendix 43
Methodology 43
Ratio Definitions 43
About GlobalData 47
Contact Us 47
Disclaimer 47
List of Tables
Swedish Orphan Biovitrum AB, Key Facts 5
Swedish Orphan Biovitrum AB, Key Employees 6
Swedish Orphan Biovitrum AB, Key Employee Biographies 7
Swedish Orphan Biovitrum AB, Major Products and Services 8
Swedish Orphan Biovitrum AB, History 9
Swedish Orphan Biovitrum AB, Subsidiaries 15
Swedish Orphan Biovitrum AB, Key Competitors 22
Swedish Orphan Biovitrum AB, Ratios based on current share price 23
Swedish Orphan Biovitrum AB, Annual Ratios 24
Swedish Orphan Biovitrum AB, Annual Ratios (Cont...1) 25
Swedish Orphan Biovitrum AB, Annual Ratios (Cont...2) 26
Swedish Orphan Biovitrum AB, Interim Ratios 28
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 30
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 31
Swedish Orphan Biovitrum AB, Recent Deals Summary 32
Currency Codes 43
Capital Market Ratios 43
Equity Ratios 44
Profitability Ratios 44
Cost Ratios 45
Liquidity Ratios 45
Leverage Ratios 46
Efficiency Ratios 46
List of Figuress
Swedish Orphan Biovitrum AB, Performance Chart (2012 - 2016)
Swedish Orphan Biovitrum AB, Ratio Charts
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Swedish Orphan Biovitrum AB, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report